The Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Hepatitis C Virus in Saudi Arabia: A Nationwide Study Based on the Saudi Ministry of Health Surveillance Data From 2017 to 2021

被引:0
|
作者
AL-Ahmari, Tasneem S. [1 ]
Alotaibi, Adel F. [2 ]
Aljasser, Areej I. [2 ]
Aljasser, Abdulrahman I. [3 ]
Eldaw, Anwar M. [4 ]
Abd-Ellatif, Eman E. [5 ]
机构
[1] Minist Hlth, Publ Hlth & Prevent Med, Riyadh, Saudi Arabia
[2] Minist Hlth, Assistance Agcy Prevent Hlth, Epidemiol, Riyadh, Saudi Arabia
[3] Huraymala Gen Hosp, Uorol, Minist Hlth, Riyadh, Saudi Arabia
[4] Minist Hlth, Infect Dis Publ Hlth & Prevent Med, Riyadh, Saudi Arabia
[5] Mansoura Univ, Fed Med, Publ Hlth & Prevent Med, Mansoura, Egypt
关键词
ministry of health (moh); effectiveness and safety; direct-acting antivirals; kingdom of saudi arabia (ksa); hepatitis c virus (hcv); SASLT PRACTICE GUIDELINES; MANAGEMENT; INFECTION;
D O I
10.7759/cureus.42780
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objective While the Kingdom of Saudi Arabia (KSA) has had a hepatitis C virus (HCV) elimination program in place since 2015, there have been limited studies investigating the effectiveness and safety of direct-acting antivirals (DAAS) based on the Ministry of Health (MOH) surveillance data. In light of this, this study was conducted to assess the effectiveness and safety of DAAS (glecaprevir/pibrentasvir, daclatasvir/sofosbuvir, or other combinations) in treating HCV cases in Saudi Arabia as per the MOH data from 2017 to 2021. Methods This was a retrospective cohort study involving recorded HCV cases in the national hepatitis surveillance database of MOH across all regions of KSA from 2017 to 2021. Statistical analyses were performed using IBM SPSS Statistics software (IBM Corp., Armonk, NY). Continuous variables were expressed as mean & PLUSMN; standard deviation (SD), and categorical variables were presented as numbers (percentages). An independent t-test was used for continuous variables, and a Chi-square analysis was used for categorical variables. A confidence interval of 95%, a margin of error of 0.05, a precision of 2%, and a 5% level of significance were employed. Results Regarding demographic characteristics, age was significantly associated with HCV infection (p=0.002). Similarly, nationality had a highly significant association with HCV infection (p=0.004). Regarding clinical characteristics, creatinine levels were significantly associated with HCV infection (p=0.009). As for effectiveness, all participants had a positive polymerase chain reaction (PCR) for HCV at enrolment (n=4806) and were DAAS-naive. After the completion of the first DAAS course, 99.5% (4781) had negative PCRs 12 weeks post-treatment completion; however, the PCR remained positive for some patients (0.5%, n=25), which became negative after receiving the second DAAS course, resulting in complete cure of HCV infection and a 100% negative PCR among all participants. With regard to safety, no side effects were recorded in the cohort and hence the safety aspect was not analyzed. Conclusion Univariate analysis revealed that nationality (non-Saudi), age, and creatinine levels were significantly associated with HCV infection. However, only nationality showed a significant association with HCV infection following multivariate logistic regression adjustment. We believe that these insights will help guide the creation of clinical guidelines and promote evidence-based decision-making in the management of HCV in Saudi Arabia.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia
    Alarfaj, Sumaiah J.
    Alzahrani, Abdullah
    Alotaibi, Anfal
    Almutairi, Malak
    Hakami, Mashael
    Alhomaid, Njood
    Alharthi, Noori
    Korayem, Ghazwa B.
    Alghamdi, Abdullah
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2022, 30 (10) : 1448 - 1453
  • [2] EFFECTIVENESS AND SAFETY OF DIRECT-ACTING ANTIVIRALS IN PSYCHIATRIC HEPATITIS C VIRUS INFECTED PATIENTS
    Margusino-Framinan, Luis
    Bobadilla-Perez, Eva
    Carlos Yanez-Rubal, Juan
    Prieto-Perez, Andrea
    Cid-Silva, Purificacion
    Rodriguez-Sotelo, Alejandro
    Gimenez-Arufe, Victor
    Quiroga-Fernandez, Candela
    Isabel Sanclaudio-Luhia, Ana
    Novo-Ponte, Ana
    Mena-De-Cea, Alvaro
    Martin-Herranz, Isabel
    Castro-Iglesias, Angeles
    [J]. HEPATOLOGY, 2019, 70 : 966A - 966A
  • [3] COST-EFFECTIVENESS OF DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C VIRUS IN RUSSIA
    Ignatyeva, V
    Pyadushkina, E.
    Derkach, E., V
    [J]. VALUE IN HEALTH, 2019, 22 : S646 - S647
  • [4] Effectiveness of Direct-acting Antivirals for the Treatment of Chronic Hepatitis C in Rwanda: A Retrospective Study
    Nsanzimana, Sabin
    Penkunas, Michael J.
    Liu, Carol Y.
    Sebuhoro, Dieudonne
    Ngwije, Alida
    Remera, Eric
    Umutesi, Justine
    Ntirenganya, Cyprien
    Mugeni, Soline D.
    Serumondo, Janvier
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 73 (09) : E3300 - E3307
  • [5] Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil
    Holzmann, Iandra
    Tovo, Cristiane V.
    Minme, Roseline
    Leal, Monica P.
    Kliemann, Michele L.
    Ubirajara, Camila
    Aquino, Amanda A.
    Araujo, Bruna
    Almeida, Paulo R. L.
    [J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2018, 22 (04): : 317 - 322
  • [6] Treatment of hepatitis C virus infection: From therapy with interferon to direct-acting antivirals
    Lopera, Laura
    Posada, Carolina
    Montoya-Guzman, Melissa
    Munoz, Daniela
    Navas, Maria-Cristina
    [J]. IATREIA, 2023, 36 (01) : 51 - 68
  • [7] Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
    El-Marakby, Mai G.
    Solayman, Mohamed H.
    Sabri, Nagwa A.
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2023, 57 (05) : 997 - 1007
  • [8] Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study
    Mai G. El-Marakby
    Mohamed H. Solayman
    Nagwa A. Sabri
    [J]. Therapeutic Innovation & Regulatory Science, 2023, 57 : 997 - 1007
  • [9] Reported adverse events related to use of hepatitis C virus direct-acting antivirals with opioids: 2017–2021
    Anthony Martinez
    Tipu Khan
    Douglas E. Dylla
    John Marcinak
    Michelle Collins
    Brad Saget
    Brian Conway
    [J]. Harm Reduction Journal, 20
  • [10] Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: From interferon-based to direct-acting antivirals era
    Cacoub, Patrice
    Vautier, Mathieu
    Desbois, Anne Claire
    Lafuma, Antoine
    Saadoun, David
    [J]. LIVER INTERNATIONAL, 2017, 37 (12) : 1805 - 1813